Does SOTORASIB Cause Interstitial lung disease? 20 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Interstitial lung disease have been filed in association with SOTORASIB (LUMAKRAS). This represents 0.7% of all adverse event reports for SOTORASIB.
20
Reports of Interstitial lung disease with SOTORASIB
0.7%
of all SOTORASIB reports
10
Deaths
7
Hospitalizations
How Dangerous Is Interstitial lung disease From SOTORASIB?
Of the 20 reports, 10 (50.0%) resulted in death, 7 (35.0%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for SOTORASIB.
What Other Side Effects Does SOTORASIB Cause?
Non-small cell lung cancer (483)
Death (319)
Disease progression (314)
Diarrhoea (284)
Off label use (193)
Nausea (98)
Non-small cell lung cancer metastatic (93)
Hepatotoxicity (91)
Fatigue (87)
Hepatic function abnormal (80)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which SOTORASIB Alternatives Have Lower Interstitial lung disease Risk?
SOTORASIB vs SOTROVIMAB
SOTORASIB vs SOVALDI
SOTORASIB vs SOYBEAN OIL
SOTORASIB vs SPARSENTAN
SOTORASIB vs SPARTALIZUMAB